摘要
目的探讨经尿道膀胱肿瘤电切(TUR-BT)术后膀胱热灌注化疗(HIVEC)治疗非肌层浸润性膀胱癌的可行性及临床初步疗效。方法回顾性分析南方医科大学中西医结合医院以及南方医科大学珠江医院2010年1月至2015年1月收治的74例非肌层浸润性膀胱癌患者,所有患者入院后均行TUR-BT术,术后按照治疗方法的不同分为治疗组和对照组。治疗组37例行膀胱热灌注化疗,对照组37例行膀胱灌注化疗。比较两组患者的治疗效果、术后2年复发率以及不良反应发生率,并进行统计学分析。结果治疗组术后2年复发率为8.1%,对照组术后2年复发率为51.4%,治疗组术后2年复发率显著低于对照组(χ~2=16.559,P<0.01)。治疗组不良反应发生率为13.5%,对照组不良反应发生率为5.4%,两组患者不良反应发生率的差异无统计学意义(χ~2=1.420,P=0.233)。结论膀胱热灌注化疗可显著降低非肌层浸润性膀胱癌患者TUR-BT术后2年复发率,且不增加相关不良反应。
Objective To investigate the primary clinical application of hyperthermic intravesical chemotherapy （HIVEC） in the prevention of non-muscle-invasive bladder cancer （NMIBC） recurrence after transurethral resection of bladder tumor （TUR-BT）. Methods The clinical data of 74 patients with NMIBC treated with TUR-BT during Jan. 2010 and Jan. 2015 were retrospectively analyzed. The patients were divided into 2 groups：the control group （n =37） underwent intravesical chemotherapy,and the treatment group （n = 37） received HIVEC. Cystoscopy was performed every 3 months after TUR-BT, and the recurrence rate was observed for 2 years. Results The 2-year recurrence rate was 8.1% and 51.4 % in the treatment group and control group,respectively. There was significant difference between the 2 groups （X2 = 16. 559, P〈0. 01）. The adverse reaction rate was 13.5% and 5.4 % in treatment group and control group. There was no statistical difference between the 2 groups （X2= 1. 420, P= 0. 233）. Gonclusion HIVEC is effective in the prevention of NMIBC recurrence for patients who have undergone TUR-BT without increasing related adverse reactions.
出处
《现代泌尿外科杂志》
CAS
2017年第12期903-906,共4页
Journal of Modern Urology
基金
南方医科大学临床研究培育项目(No.LC2016PY051)
关键词
非肌层浸润性膀胱癌
经尿道膀胱肿瘤电切术
膀胱热灌注化疗
2年复发率
non-muscle-invasive bladder cancer
transurethral resection of bladder tumor
hyperthermic intravesical chem- otherapy
2-year recurrence rate
